FDA expands use of Pfizer’s Prevnar
US regulators have expanded the scope of Pfizer’s pneumococcal vaccine Prevnar 13, allowing its use in adults aged 18 to 49 years of age.
Read More
Tag: Prevnar 13
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
